WO2014160645A3 - Tumeurs neuroendocrines - Google Patents

Tumeurs neuroendocrines Download PDF

Info

Publication number
WO2014160645A3
WO2014160645A3 PCT/US2014/031587 US2014031587W WO2014160645A3 WO 2014160645 A3 WO2014160645 A3 WO 2014160645A3 US 2014031587 W US2014031587 W US 2014031587W WO 2014160645 A3 WO2014160645 A3 WO 2014160645A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuroendocrine tumors
samples
ffpe
classify
identify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/031587
Other languages
English (en)
Other versions
WO2014160645A2 (fr
Inventor
Catherine A. Schnabel
Yi Zhang
Mark G. Erlander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheranostics Inc
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Priority to CA2905620A priority Critical patent/CA2905620A1/fr
Publication of WO2014160645A2 publication Critical patent/WO2014160645A2/fr
Publication of WO2014160645A3 publication Critical patent/WO2014160645A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés pour l'utilisation de mesures d'expression génique pour classer ou identifier un cancer neuroendocrine dans des échantillons obtenus à partir d'un sujet dans un réglage clinique, tel que dans des cas d'échantillons fixés en formaline, inclus en paraffine (FFPE).
PCT/US2014/031587 2013-03-15 2014-03-24 Tumeurs neuroendocrines Ceased WO2014160645A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2905620A CA2905620A1 (fr) 2013-03-15 2014-03-24 Tumeurs neuroendocrines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361802063P 2013-03-15 2013-03-15
US61/802,063 2013-03-25

Publications (2)

Publication Number Publication Date
WO2014160645A2 WO2014160645A2 (fr) 2014-10-02
WO2014160645A3 true WO2014160645A3 (fr) 2014-12-31

Family

ID=51211842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/031587 Ceased WO2014160645A2 (fr) 2013-03-15 2014-03-24 Tumeurs neuroendocrines

Country Status (3)

Country Link
US (3) US20140349856A1 (fr)
CA (1) CA2905620A1 (fr)
WO (1) WO2014160645A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (fr) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Prédiction de l'évolution d'un cancer
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (fr) 2009-05-07 2018-09-26 Veracyte, Inc. Procédés pour le diagnostic d'affections thyroïdiennes
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2885640B1 (fr) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prognostic du cancer de la prostate au moyen de biomarqueurs
EP2968988A4 (fr) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (fr) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
WO2018132916A1 (fr) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Sous-typage moléculaire, pronostic et traitement du cancer de la vessie
CA3055925A1 (fr) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour predire la reponse a une therapie hormonale
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (fr) 2017-08-04 2019-02-07 Genomedx, Inc. Utilisation d'une expression génique spécifique des cellules immunitaires pour le pronostic du cancer de la prostate et la prédiction de la sensibilité à la radiothérapie
WO2019079792A1 (fr) 2017-10-20 2019-04-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédé de distinction entre un carcinome urothélial et un carcinome à cellules squameuses bronchopulmonaire et de la tête et du cou
AU2021268631A1 (en) * 2020-05-04 2023-01-05 Mayo Foundation For Medical Education And Research Detecting pancreatic neuroendocrine tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116380A2 (fr) * 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Modèle hybride de classification de sous-types de carcinome
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2013002750A2 (fr) * 2011-06-29 2013-01-03 Biotheranostics, Inc. Détermination de l'origine d'une tumeur

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1820100A (en) 1998-11-13 2000-06-05 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US7364846B2 (en) 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2548514T3 (es) 2004-06-04 2015-10-19 Biotheranostics, Inc. Identificación de tumores
DK1899484T3 (da) 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116380A2 (fr) * 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Modèle hybride de classification de sous-types de carcinome
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2013002750A2 (fr) * 2011-06-29 2013-01-03 Biotheranostics, Inc. Détermination de l'origine d'une tumeur

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONES ET AL: "Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles", THE LANCET, THE LANCET PUBLISHING GROUP, GB, vol. 363, no. 9411, 6 March 2004 (2004-03-06), pages 775 - 781, XP005061490, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(04)15693-6 *
SARAH E KERR ET AL: "A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors", MODERN PATHOLOGY, vol. 27, no. 1, 1 January 2014 (2014-01-01), pages 44 - 54, XP055152140, ISSN: 0893-3952, DOI: 10.1038/modpathol.2013.105 *
XIAO-JUN MA ET AL: "Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1 April 2006 (2006-04-01), United States, pages 465 - 473, XP055151830, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16594740> [retrieved on 20141111] *

Also Published As

Publication number Publication date
US20230287511A1 (en) 2023-09-14
US12595516B2 (en) 2026-04-07
WO2014160645A2 (fr) 2014-10-02
US20140349856A1 (en) 2014-11-27
CA2905620A1 (fr) 2014-10-02
US11549148B2 (en) 2023-01-10
US20180135131A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
WO2014160645A3 (fr) Tumeurs neuroendocrines
WO2014018563A3 (fr) Procédés pour le traitement du cancer
DK3030255T3 (da) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
EP3194624A4 (fr) Méthodes pour le diagnostic, le pronostic et la surveillance du cancer du sein et réactifs correspondants
EP3119908A4 (fr) Détermination de l&#39;agressivité d&#39;un cancer, de son pronostic et de sa sensibilité à un traitement
EP3816303A3 (fr) Kit ou dispositif de détection du cancer du sein et procédé de détection du cancer du sein
EP4060048A3 (fr) Procédé de diagnostic non invasif pour diagnostiquer un cancer de la vessie
IL295031B1 (en) Innovative immunotherapy against several tumors, such as lung cancer, including nsclc
EP3008210A4 (fr) Procédés pour détecter le cancer de la prostate
EP3011055A4 (fr) Système de classification, procédé et trousse pour la classification, la prédiction et le traitement d&#39;un cancer du sein
EP2988131A4 (fr) Marqueur génétique pour la prédiction pronostique et le diagnostic précoces du cancer du sein et leur utilisation
EP4202441A3 (fr) Profil d&#39;expression génétique dans les macrophages pour le diagnostic du cancer
EP3098311A4 (fr) Procédé de mesure de nucléobase modifiée faisant appel à une sonde guide, et kit associé
HK1220253A1 (zh) 诊断前列腺癌症的方法
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
WO2013124738A3 (fr) Méthodes et biomarqueurs permettant de dépister et de pronostiquer le cancer du col utérin
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
WO2014197835A3 (fr) Méthodes et compositions pour le traitement du cancer
EP3094976A4 (fr) Antigène de surface cellulaire du cancer de la prostate destiné au diagnostic
WO2015035403A3 (fr) Procédés d&#39;évaluation de la croissance tumorale
EP3058101A4 (fr) Des micro-arn de sérum pour le pronostic du cancer de la prostate
EP3063689A4 (fr) Procédés d&#39;incorporation d&#39;informations de locus chromosomique de transcription pour l&#39;identification de biomarqueurs de risque de récurrence de maladies
EP3888671A3 (fr) Formulations protéiques
WO2013002750A3 (fr) Détermination de l&#39;origine d&#39;une tumeur

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2905620

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 241584

Country of ref document: IL

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14741697

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14741697

Country of ref document: EP

Kind code of ref document: A2